Multiomic liquid biopsy: emerging applications in disease quantification, biomarker detection, molecular phenotyping, and cancer signal of origin prediction
4 affiliations
- 1Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center
- 2Guardant Health, Inc.
- 3Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center
- 4Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University
Abstract
The field of cancer-related liquid biopsy, largely defined as plasma circulating tumor DNA (ctDNA) analysis by next-generation sequencing (NGS), is rapidly evolving from genomics-only approaches to multiomic assays that add components such as DNA fragmentomics and epigenomics, with or without proteomics, to a genomic backbone. Here we describe how integration of epigenomic profiling, particularly tumor-specific methylation signatures, may extend ctDNA testing beyond detection of genomic alterations toward broader molecular phenotyping, with applications in alternative approaches to tumor fraction quantification, enhanced detection of actionable genomic biomarkers and mechanisms of resistance, histologic and lineage characterization, and cancer signal of origin prediction. This evolution has facilitated the clinical application of liquid biopsy across the cancer care continuum, from screening/early detection to determining minimal residual disease (MRD) in early-stage cancers to selecting treatment and determining mechanisms of acquired resistance in advanced-stage cancers. These new multiomic assays may also support prospective biomarker-driven clinical trials incorporating complementary measures of tumor burden, genomic alterations, and molecular phenotype. Collectively, these advances suggest that multiomic liquid biopsy platforms may represent a major advance in precision oncology, enabling dynamic and comprehensive characterization of tumor biology.
Related
- Cluster-Based Phenotyping in an HFpEF Population Identifies a Biomarker-High, Atrial-Dysfunction Phenotype with Impaired Quality of Life, Reduced Exercise Capacity and Higher Healthcare Utilization
- Integrated multiomic scores for cardiovascular disease prediction across multiancestral populations
- Continuous Glucose Monitoring for Metabolic Phenotyping and Precision Nutrition: Current Evidence, Clinical Applications and Future Perspectives
- Biomarker-Informed Phenotyping of the Heart Failure Continuum: A Population-Based Evaluation of the Second Universal Definition of Heart Failure
- Preoperative 3D morphological phenotyping of hepatocellular carcinoma via a foundation model: a non-invasive biomarker for recurrence risk stratification.
BibTeX
@article{gheeya2026multiomic,
title = {{Multiomic liquid biopsy: emerging applications in disease quantification, biomarker detection, molecular phenotyping, and cancer signal of origin prediction}},
author = {Jinesh S. Gheeya and Lauren Welch and Jason Porter and Sean Gordon and Jonathan Riess and Shirish Gadgeel and David R. Gandara},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1984602},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1984602/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Multiomic liquid biopsy: emerging applications in disease quantification, biomarker detection, molecular phenotyping, and cancer signal of origin prediction
AU - Jinesh S. Gheeya
AU - Lauren Welch
AU - Jason Porter
AU - Sean Gordon
AU - Jonathan Riess
AU - Shirish Gadgeel
AU - David R. Gandara
PY - 2026
DA - 2026/11/02
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1984602
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1984602/full
AB - The field of cancer-related liquid biopsy, largely defined as plasma circulating tumor DNA (ctDNA) analysis by next-generation sequencing (NGS), is rapidly evolving from genomics-only approaches to multiomic assays that add components such as DNA fragmentomics and epigenomics, with or without proteomics, to a genomic backbone. Here we describe how integration of epigenomic profiling, particularly tumor-specific methylation signatures, may extend ctDNA testing beyond detection of genomic alterations toward broader molecular phenotyping, with applications in alternative approaches to tumor fraction quantification, enhanced detection of actionable genomic biomarkers and mechanisms of resistance, histologic and lineage characterization, and cancer signal of origin prediction. This evolution has facilitated the clinical application of liquid biopsy across the cancer care continuum, from screening/early detection to determining minimal residual disease (MRD) in early-stage cancers to selecting treatment and determining mechanisms of acquired resistance in advanced-stage cancers. These new multiomic assays may also support prospective biomarker-driven clinical trials incorporating complementary measures of tumor burden, genomic alterations, and molecular phenotype. Collectively, these advances suggest that multiomic liquid biopsy platforms may represent a major advance in precision oncology, enabling dynamic and comprehensive characterization of tumor biology.
SN - 2234-943X
ER -